Research on the biology of the pneumococcus and pneumococcal diseases: the number one cause of death in children worldwide. by Vidal, Jorge Eugenio
EDITORIAL
5Horizonte sanitario  /  vol. 16,  no. 1, enero-abril 2017
http://revistas.ujat.mx/index.php/horizonte
Streptococcus pneumoniae has been for decades the number 
one bacterial killer of children in the world. Although 
vaccination with pneumococcal conjugate vaccines [PCV7, 
PCV10, and PCV13 (children) or PPSV23(adults)] has 
helped decrease the burden of pneumococcal disease (PD), 
mortality remains high. The introduction of pneumococcal 
vaccines has also created a niche for vaccine-escape clones. 
Moreover, the rise of multidrug resistant clones around 
the world has also posed a serious threat in recent years. 
Rapid and accurate identification of the pneumococcus in 
patients suspected of having PD is a high priority as rapid 
identification of the etiology will lead to better outcomes 
and thus may help in reducing mortality associated with PD. 
Efforts have been made for the last ten years in my laboratory 
to get insights into the biology of the pneumococcus and 
pneumococcal genetics in order to develop knowledge 
and tools to assist in decreasing the burden of disease. 
In my laboratory, a translation science laboratory, we 
have undertaken or participated in basic science studies, 
epidemiological studies around the world, clinical trials of 
new potential antibiotics, and we have spent several years 
developing and validating molecular technology to identify 
the pneumococcus and its 90+ serotypes.
Streptococcus pneumoniae: a commensal and a pathogen 
The Gram-positive bacterium Streptococcus pneumoniae 
(the pneumococcus) is a common asymptomatic resident 
of the human upper airways including the nasopharynx 
and oropharynx, but it is also a primary etiologic agent 
in pneumonia, otitis media, meningitis, and sepsis. 
Pneumococcal pneumonia is the leading cause of childhood 
death in developing countries, killing around one million 
children every year, while also causing a significant 
burden of morbidity, mortality, and healthcare costs in 
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developed countries such as the United States. Colonization 
of the nasopharynx, while not an immediate cause of 
pneumococcal disease, is a necessary step along the path to 
pneumococcal disease. Pneumococcal colonization has been 
a primary focus of the investigations in my laboratory at 
Emory University, which will be detailed in the subsequent 
sections. 
 
Studies of colonization and serotype replacement. 
Despite taking the lives of many children every year, the 
pneumococcus is carried in the nasopharynx by ~90% of 
children1. For example, our 2009 study in Peru demonstrated 
a very high carriage prevalence in healthy children. 
Approximately half of the isolated strains belonged to a 
serotype targeted by the PCV7 vaccine and therefore the 
most likely to produce PD 2. PCV7 was introduced late 
in 2009 in Peru and in follow-up studies two years later 
(2011) we demonstrated that carriage prevalence had 
remained similarly high, although we observed serotype 
replacement, i.e. a significant decrease of serotypes targeted 
by the vaccine, which were replaced by vaccine-escape 
serotypes 3. Whether this change in the serotypes that 
children carry after the introduction of PCV7 has changed 
the burden of disease remains to be elucidated. In any 
case, carriage of potential human pathogens poses a risk 
of disease. We recently described, in a study conducted in 
Tanzania, a strong association between lower respiratory 
tract infection, including clinical pneumonia, and carriage 
of  S. pneumoniae, Haemophilus influenza and Moraxella 
catarrhalis4.  Pneumococcal serotypes were not investigated. 
In Mexico, the pneumococcal vaccine PCV7 was introduced 
by the national immunization program in 2008, and by 2013, 
it was replaced by a vaccine with extended coverage: PCV13. 
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Whereas the burden of disease in Mexico, mirroring similar 
trends around the world, has decreased post introduction 
of pneumococcal vaccines, to the best of my knowledge, 
studies of colonization in the country have not yet been 
conducted. This is an important piece of information given 
that colonization is a required step towards the development 
of pneumococcal disease. 
Development of technology to identify and serotype 
pneumococcal strains. 
Five years ago, we were fortunate enough to be invited by 
the Bill and Melinda Gates Foundation in the USA, and 
the Murdoch Children Research Institute in Australia, to 
participate in a global consortium aiming to develop new 
molecular methods for the identification and serotyping of 
pneumococcal strains5. We developed more than 70 single-
plex quantitative PCR reactions that identify and quantify 
the bacterial load of most pneumococcal serotypes known to 
date6. These reactions represent a significant breakthrough 
since, prior to our studies, available molecular reactions 
only targeted ~25% of pneumococcal strains. All of these 
single-plex reactions were recently multiplexed into a high-
throughput platform known as a Taqman array card (TAC) 
which in a single reaction detects most pneumococcal 
serotypes with high sensitivity and specificity7. The TAC 
technology, along with other technologies developed by 
the consortium, will be implemented during the years to 
come to monitor the burden of PD as well as the efficacy of 
pneumococcal vaccines.
Nasopharyngeal colonization.
Compelling evidence from my laboratory and others 
has demonstrated that the pneumococcus colonizes 
the nasopharynx forming bacterial aggregates, which, 
for simplicity in this editorial, I will call biofilms. 
Nasopharyngeal biofilms allow the pneumococcus to 
persist in the human population. Controlling pneumococcal 
colonization may be a way to reduce the burden of disease, 
and so biofilm research has been a focus of basic science 
studies in my laboratory. We developed a life-like model that 
simulates the human upper and lower airways to investigate 
production of colonizing biofilms8. The last few years, we 
have learned that pneumococcal biofilms are controlled 
by quorum sensing, small molecules that activates other 
mechanisms of virulence 9, including a potent toxin known 
as pneumolysin or Ply10. Thanks to a grant funded by the 
National Institutes of Health (NIH) of the USA, we are 
now focusing on investigating population dynamics of 
bacterial consortiums in the human nasopharynx, including 
recombination leading to the appearance of new serotypes 
and the emergence of new antibiotic resistant strains. 
These studies are now beginning to provide explanations 
for observations we have made in epidemiological studies, 
including the negative association for carriage of the 
pneumococcus and Staphylococcus aureus in the human 
nasopharynx. On this regard, we recently demonstrated 
that pneumococcus kills Staphylococcus aureus strains by 
physical contact11. Besides explaining why, they do not get 
along together in the human upper airways, our data has 
opened up a new area of investigation as S. aureus strains 
are known to be important nosocomial pathogens. Having 
new tools to eradicate strains of  S. aureus is a priority given 
the high burden of antibiotic resistance clones isolated in 
clinical studies. 
From the nasopharynx to cause disease. 
Despite being such as successful pathogen, and for reasons 
we do not yet understand, epidemiological studies have 
demonstrated that  the pneumococcus persists in the 
nasopharynx of colonized children for only ~60 days, 
whereas the adult is colonized for ~30 days1,12. On entering 
the nasopharynx, and during its residence there, the 
pneumococcus shares this anatomical and physiological 
niche with an array of other viral and bacterial inhabitants. 
From the nasopharynx, and by a mechanism under active 
investigation, the pneumococcus migrates to the ear 
epithelium to cause otitis media, or it goes down into the 
lungs causing pneumonia. Invasive pneumonia is a severe 
form of pneumococcal pneumonia that becomes bacteremic. 
Pneumococcal meningitis is another lethal presentation of 
pneumococcal disease that can be caused by invasion of 
the meninges (the membranes covering the brain and spinal 
cord) by bacteria in circulation in septicemic patients, or 
bacteria translocated directly from the infected ear to the 
meninges. Understanding how pneumococcus migrates 
though the lung epithelium to the circulation is a current hot 
spot in my laboratory. We hypothesize that if we identify 
the molecular mechanism, ie., targets on lung cells utilized 
by pneumococcus to get inside the cells and move into the 
bloodstream, we should be able to propose new therapeutic 
approaches aiming to avoid lethal invasive disease. 
Remarks
Pneumococcal disease remains a serious threat to humans, 
especially for children and the elderly, and the burden 
of disease is particularly high in developing countries, 
including Mexico. As we develop vaccines and new 
antibiotics for prevention and therapeutics aimed to control 
PD, these bacteria evolve to successfully persist in the 
human population and, perhaps involuntarily, cause damage 
leading to high mortality rates. We in the field, from different 
fronts, are combining efforts to identify the best ways to 
control pneumococcal infections. 
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